Table 1 Characteristics of Patients with Carbapenem-resistant Pseudomonas aeruginosa (CRPA) infections according to antibiotic treatments (monotherapy vs combination regimen)

Age(year)

66(56,75)

67(56,75)

65(56,75)

Male,n(%)

180(64.5%)

59 (63.4%)

121 (65.1%)

Ethnicity,n(%)

 White

196(70.3%)

63(67.7%)

133(71.5%)

 Black/African American

29(10.4%)

12(12.9%)

17(9.1%)

 Others

54(19.4%)

18(19.4%)

36(19.4%)

Comorbidity,n(%)

 Hypertension

68(24.4%)

21(22.6%)

47(25.3%)

 Diabetes

109(39.1%)

46(49.5%)

63(33.9%)

 Myocardial infarction

42(15.1%)

16(17.2%)

26(14.0%)

 Chronic pulmonary disease

90(32.3%)

25(26.9%)

65(34.9%)

 Cerebrovascular disease

36(12.9%)

15(16.1%)

21(11.3%)

 Renal disease

83(29.7%)

29(31.2%)

54(29.0%)

 Severe liver disease

13(4.7%)

5(5.4%)

8(4.3%)

Laboratory test

 White cell count(*10⁹/l)

10.77(7.80,15.20)

10.50(7.93,14.60)

10.81(7.50,15.70)

 Hemoglobin( g/dl)

8.70(7.97,9.70)

8.70(7.93,9.90)

8.73(7.97,9.70)

 Platelet (*10⁹/l)

221.67(144.33,328.00)

249.75(155.00,345.00)

218.67(134.57,322.33)

 Creatinine(mg/dl)

0.90(0.60,1.53)

1.00(0.70,1.60)

0.90(0.60,1.53)

Site of infection,n(%)

 Respiratory tract

138(49.5%)

42(45.2%)

96(51.6%)

 Urinary tract

54(19.4%)

20(21.5%)

34(18.3%)

 Bloodstream

24(8.6%)

5(5.4%)

19(10.2%)

 Other

63(22.6%)

26(28.0%)

37(19.9%)

Ventilation,n(%)

97(34.8%)

27(29.0%)

70(37.6%)

Septic shock,n(%)

50(17.9%)

11(11.8%)

39(21.0%)

Charlson Comorbidity Score

6(4,8)

6(5,8)

6(4,8)

SOFA score

4(1,7)

3(1,6)

4(1,7)

Outcome,n(%)

 Clinical success

192(68.8%)

56(60.2%)

136(73.1%)

 Complete clinical success

109(39.1%)

51(36.2%)

58(42.0%)

 28-day mortality

49(17.6%)

14(15.1%)

35(18.8%)